AbbVie completed the acquisition of Allergan for $63bn.

AbbVie, a researcher and developer of pharmaceutical products, completed the acquisition of Allergan, a manufacturer of speciality pharmaceuticals for $63bn. Allergan shareholders received 0.8660 AbbVie Shares and $120.30 in cash for each Allergan share, for a total consideration of $193.23 per Allergan share. "We are pleased to reach this important milestone for the Company, its employees, shareholders and the patients we serve. Our new Allergan colleagues should be commended for all their efforts, along with those of our own employees, to achieve this turning point for our Company. I am proud of both organizations and look forward to the opportunities ahead," Richard A. Gonzalez, AbbVie CEO.